Patents Assigned to Novartis
  • Patent number: 6362164
    Abstract: A combination of a compound of the somatostatin class and a rapamycin macrolide is useful for the prevention or treatment of cell hyperproliferation.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: March 26, 2002
    Assignee: Novartis AG
    Inventor: Gisbert Weckbecker
  • Patent number: 6358719
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 19, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6358925
    Abstract: A method for the treatment or prevention of osteoporosis in higher mammals is disclosed, the method comprising administering Insulin-like Growth Factor I (IGF-I) in an effective amount thereof to said mammal, said mammal being in need of said treatment or prevention. Compositions for pharmaceutical use in the above method are also described.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: March 19, 2002
    Assignee: Novartis Corp.
    Inventors: Hans-Peter Guler, Satish Bhatia
  • Patent number: 6355457
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355459
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6355458
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6353030
    Abstract: A polylactide in a purified state, which meets the requirements of the color strengths of reference solutions B2-B9 of the brown color test of the European Pharmacopoeia, 2nd Edition (1980) part I, Section V, 6.2 and containing one or more metals in cationic form, the metal ion(s) having a concentration of at most 10 ppm. The polylactide is especially suitable for use as microparticles or implants, and contains preferably a hydrophilic drug, like octreotide or a lipophilic drug like bromocriptine.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: March 5, 2002
    Assignee: Novartis AG
    Inventor: Walter Prikoszovich
  • Patent number: 6353017
    Abstract: N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.
    Type: Grant
    Filed: August 22, 2000
    Date of Patent: March 5, 2002
    Assignee: Novartis AG
    Inventors: Eva Altmann, Claudia Betschart, Keigo Gohda, Miyuki Horiuchi, Rene Lattmann, Martin Missbach, Junichi Sakaki, Michihiro Takai, Naoki Teno, Scott Douglas Cowen, Paul David Greenspan, Leslie Wighton McQuire, Ruben Alberto Tommasi, John Henry van Duzer
  • Patent number: 6352998
    Abstract: This invention provides a topical composition, in the form of an emulsion, that comprises a compound of the FK506 class; a physiologically acceptable alkanediol, ether diol or diether alcohol containing up to 8 carbon atoms as solvent for the compound of the FK506 class; an unsaturated fatty alcohol and water. In another aspect, this invention provides a topical pharmaceutical composition that comprises a macrolide in suspension. In a further aspect, this invention provides the use of an unsaturated fatty alcohol to stabilize a macrolide in a pharmaceutical composition.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: March 5, 2002
    Assignee: Novartis AG
    Inventors: Martin Jackman, Xue-Ping Popp, Friedrich Richter, Fritz Schmook
  • Patent number: 6350878
    Abstract: The invention relates to a method of synthesis for a compound of formula (I), wherein R is a heterocyclyl moiety and X1, X2, X3 and X4 are, independently of each other, protecting groups, which is appropriate for the synthesis of epothilone B and desoxyepothione B.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: February 26, 2002
    Assignee: Novartis AG
    Inventors: Karl-Heinz Altmann, Armin Bauer, Dieter Schinzer
  • Patent number: 6346626
    Abstract: The invention concerns the compounds of formula I wherein R1 and R2 independently are hydrogen, acyl, alkoxycarbonyl or alkyl; either the sulfamoyloxy side chain is bound to the 6 position; R3 is alkyl; alkenyl; alkinyl; a cycloalkyl moiety optionally substituted by alkyl, alkoxy or halogen; arylalkenyl; arylalkinyl; acyl; cycloalkylalkyl; 3-oxo-2-oxacamphanyl; or is 6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl; and R4 is hydrogen; alkyl; hydroxy; or alkoxy; or the sulfamoyloxy side chain is bound to the 7 position; R3 has the significance indicated above for R4; and R4 has the significance indicated above for R3; X is O or S; and the symbol - - - is a single or a double bond; in free form or salt form. They can be prepared by sulfamoylation of corresponding hydroxylated compounds, by reduction and/or by N-substitution. They are indicated for use as pharmaceuticals, particularly in the prophylactic or curative treatment of illnesses responsive to steroid sulfatase inhibition.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: February 12, 2002
    Assignee: Novartis AG
    Inventors: Andreas Billich, Peter Nussbaumer, Erwin Schreiner, Ingeborg Schuster
  • Patent number: 6346404
    Abstract: Nucleic acid molecules are isolated from Sorangium cellulosum that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: February 12, 2002
    Assignee: Novartis AG
    Inventors: Thomas Schupp, James Madison Ligon, Istvan Molnar, Ross Zirkle, Devon Dawn Cyr, Jörn Görlach
  • Patent number: 6342570
    Abstract: The present invention describes novel statistical copolymers and the preparation and possible uses thereof. Copolymers are described that are water-soluble and cross-linkable and that comprise the copolymerization product of a monomer mixture consisting substantially of a vinyl lactam (a) and at least one further vinyl monomer (b) of a different type selected from the group consisting of hydrophobic, hydrophilic and functional vinyl monomers, wherein the monomers are present in the copolymer in the form of statistically distributed building blocks, and, if a functional vinyl monomer is present as a building block in the copolymer, that building block is, where appropriate, modified with a reactive vinyl monomer (c), the reactive vinyl monomer (c) being linked to a building block of a functional vinyl monomer with retention of its vinylic group and with the formation of a covalent bond.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: January 29, 2002
    Assignee: Novartis AG
    Inventors: Harald Bothe, Achim Müller, Bernhard Seiferling, Sharla Borghorst, John Golby, Peter Hagmann, Peter Herbrechtsmeier, Otto Kretzschmar
  • Patent number: 6340754
    Abstract: The invention relates to a compound of formula (I) Wherein: B is adenine, guanine or hypoxanthine Z is hydrogen or a negative charge R is —[CH2CH(R1)—O]n—R2, —CH2CH2X, in which R1 is hydrogen or (C1-C6) alkyl R2 is hydrogen or (C1-C6) alkyl n is a number from 1 to 6 X is OH, F, NR3R4 R3 and R4 are independently from each other hydrogen or (C1-C6) alkyl and to methods of enzymatically treating these compounds with biocatalysts having cyclic phosphodiesterase activity.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: January 22, 2002
    Assignee: Novartis AG
    Inventors: Oreste Ghisalba, Guy Joel Christian Marais, Pierre Martin
  • Patent number: 6338822
    Abstract: A sensor for the optical determination by fluorescence of carbon dioxide in liquid and gaseous media, which consist essentially of a carrier and a light-sensitive layer applied thereto. In addition to a polymer as a base substance and an anionic fluorescence dye, the light-sensitive layer also contains a quaternary onium phenolate.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: January 15, 2002
    Assignee: Novartis AG
    Inventors: Adrian Waldner, Steven Mark Barnard
  • Patent number: 6338407
    Abstract: A child-resistant, adult friendly package is disclosed. The package is designed to require a sequence of opening steps too complex for a child to perform, but simple enough for an adult to perform. The package is formed from a top having a surface that projects from one face of the top sheet and forms a recess in the opposite face of the top sheet, a bottom sheet overlying the opposite face of the top sheet, arranged to enclose the recess, a sealed portion and an unsealed portion formed between the top sheet and the bottom sheet, wherein each recess is associated with a sealed portion and an unsealed portion, and a tear slit located between the unsealed portion and an edge of the package, wherein the tear slit does not contact any edge of the package.
    Type: Grant
    Filed: March 13, 2001
    Date of Patent: January 15, 2002
    Assignee: Novartis Pharmaceuticals Corp.
    Inventor: David Roy Danville
  • Patent number: 6335031
    Abstract: Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: January 1, 2002
    Assignees: Novartis AG, LTS Lohmann Therapie-Systeme GmbH Co. KG
    Inventors: Bodo Asmussen, Michael Horstmann, Kai Köpke, Henricus L. G. M. Tiemessen, Steven Minh Dinh, Paul M. Gargiulo
  • Patent number: 6332877
    Abstract: A catheter or ostomy tube placement tip is comprised of a tapered, substantially conical head portion and a cylindrical body or stem portion centrally attached to the base thereof. The cylindrical base fits snugly within the lumen of a catheter or ostomy tube such as a ostomy or jejunal feeding tube and its tapered design allows for the insertion and placement of the tube within the lumen of the stomach or other body cavity through an opening or ostomy. Once properly placed, the tip is discharged from the end of the tube so that it is dissolved by human body fluids and is excreted.
    Type: Grant
    Filed: May 12, 1998
    Date of Patent: December 25, 2001
    Assignee: Novartis AG
    Inventor: Lester D. Michels
  • Patent number: D451806
    Type: Grant
    Filed: October 14, 1999
    Date of Patent: December 11, 2001
    Assignee: Novartis Nutrition AG
    Inventor: Thomas Stalder
  • Patent number: PP12452
    Abstract: A new Verbena plant particulary distinguished by its large violet blue flower, early flowering, and a spreading habit.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: March 12, 2002
    Assignee: Novartis Seed B.V.
    Inventor: Henricus G. W. Stemkens